Observational studyEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Clinical features and risk factors for severe macrolide-resistant mycoplasma pneumoniae pneumonia induced by 23 S rRNA A2063G mutation: a retrospective observational study.
Observational study in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Qingxuan Zhike Granules Modulate Gut Dysbiosis and Enhance Intestinal Repair in MurineJournal of microbiology and biotechnology · 2026Article
- A retrospective clinical risk prediction model for co‑infection with Mycoplasma pneumoniae in patients with COVID‑19 based on restricted cubic splines.Scientific reports · 2026Article
- Clinical utility of the targeted next-generation sequencing for detection of Mycoplasma pneumoniae and antimicrobial resistance genes for adults.BMC infectious diseases · 2026Article
- A Novel Nomogram Integrating Clinical, Radiological, and Immunological Indicators for Early Prediction of SevereJournal of inflammation research · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Construction of a nomogram combining CT and serum markers for predicting macrolide resistance gene mutation status in pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Article
- Machine learning-driven risk assessment of severeFrontiers in medicine · 2026Article
- Clinical characteristics ofTranslational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the clinical characteristics and risk factors of severe macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMP) induced by the 23 S rRNA A2063G mutation.
methodsClinical data were collected from 526 pediatric patients diagnosed with Mycoplasma pneumoniae pneumonia (MPP) at Kunming Children's Hospital, representing a single-center cohort study conducted between October 2023 and February 2024. Among them, 483 cases (91.83%) tested positive for the 23 S rRNA A2063G mutation. Patients were categorized into severe (n = 192) and general (n = 291) groups based on clinical severity. Univariate and multivariate logistic regression analyses were performed to identify risk factors for severe MRMP.
resultsUnivariate analysis revealed that the severe group had younger age, longer disease duration, higher peak fever temperatures, and prolonged fever duration compared to the general group. The incidence of wheezing, dyspnea, and decreased breath sounds was significantly higher in the severe group. Radiological findings indicated a higher prevalence of pulmonary consolidation, atelectasis, pleural effusion, and multi-lobar involvement in the severe group. Laboratory tests showed elevated levels of neutrophils, platelets, liver enzymes, lactate dehydrogenase (LDH), D-dimer, and erythrocyte sedimentation rate, alongside reduced levels of albumin, blood urea nitrogen, and creatinine in the severe group. Regarding treatment, doxycycline was the primary alternative for MRMP, but fluoroquinolones were more frequently administered in the severe group, along with a significantly higher usage of glucocorticoids. Additionally, oxygen therapy was more commonly required in the severe group, with 2% of patients necessitating mechanical ventilation or admission to the pediatric intensive care unit. Compared to the general group, the severe group had significantly longer hospital stays (P < 0.01), prolonged lung rales, slower decline in inflammatory markers, and delayed radiological improvement. However, no fatalities were recorded in this cohort. Multivariate logistic regression analysis identified prolonged fever duration, multi-lobar consolidation, elevated LDH, and increased D-dimer levels as independent risk factors for severe MRMP. Receiver Operating Characteristic (ROC) curve analysis demonstrated that the combination of fever duration, multi-lobar consolidation, LDH, and D-dimer had high sensitivity and specificity for diagnosing severe MRMP, with an area under the curve (AUC) of 0.90.
conclusionProlonged fever duration, multi-lobar consolidation, elevated LDH, and increased D-dimer levels are key predictive indicators for severe MRMP. Although severe MRMP is associated with a prolonged clinical course and complex treatment, timely adjustment of antibiotic regimens and supportive care can effectively improve outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40676488What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.